Solid Tumor Clinical Trials in Chicago, Illinois

16 studies are recruiting for solid tumor in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Local Institution - 124, Chicago, Illinois

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

2. PRE-ISPY Phase I/II Oncology Platform Program

   PRE-ISPY Phase I/II (I-SPY-P1) is an open-label, multisite platform study with multiple ongoing drug regimen arms added by protocol amendment which is designed to evaluate single agents or combinations in locally advanced, incurable, or metastatic solid tumors and/or oligometastatic malignancy and/…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois

   Locations

   10 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT05868226 on ClinicalTrials.gov

3. A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

   This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with advanced or metastatic…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Illinois, Chicago, Illinois

   Locations

   42 in total

   Run by

   Genentech, Inc.

   See if you can join NCT06619587 on ClinicalTrials.gov

4. SMP-3124LP in Adults With Advanced Solid Tumors

   An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern Medicine Cancer Center, Chicago, Illinois

   Locations

   12 in total

   Run by

   Sumitomo Pharma America, Inc.

   See if you can join NCT06526819 on ClinicalTrials.gov

5. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

   This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Exelixis Clinical Site #26, Chicago, Illinois

   Locations

   122 in total

   Run by

   Exelixis

   See if you can join NCT05176483 on ClinicalTrials.gov

6. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

   This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   The University of Chicago Medical Center, Chicago, Illinois

   Locations

   42 in total

   Run by

   Inhibrx Biosciences, Inc

   See if you can join NCT04198766 on ClinicalTrials.gov

7. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

   Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesench…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medical Center, Chicago, Illinois

   Locations

   41 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04939610 on ClinicalTrials.gov

8. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

   Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be removed with surgery * Relapsed, which means cancer has come back …

   Stage

   Phase 1

   Ages

   0 to 17

   Site

   Call for Information (Investigational Site 0024), Chicago, Illinois

   Locations

   16 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT02332668 on ClinicalTrials.gov

9. A Study of PYX-201 in Advanced Solid Tumors

   The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with recurrent/metastatic (R/M) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Medicine, Chicago, Illinois

   Locations

   29 in total

   Run by

   Pyxis Oncology, Inc

   See if you can join NCT05720117 on ClinicalTrials.gov

10. An Extension Study for Patients Previously Enrolled in Studies With Pelabresib

    The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Locations

    15 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT06401356 on ClinicalTrials.gov

11. A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

    The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer [OC], endometrial cancer [EC], non-sma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northwestern Memorial Hospital, Chicago, Illinois

    Locations

    58 in total

    Run by

    Eisai Inc.

    See if you can join NCT04300556 on ClinicalTrials.gov

12. VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

    This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.

    Stage

    Phase 1

    Ages

    0 to 30

    Site

    Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

    Locations

    7 in total

    Run by

    University of Texas Southwestern Medical Center

    See if you can join NCT04796012 on ClinicalTrials.gov

13. A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

    The purpose of this study is to find out whether selinexor is an effective treatment for people who have a relapsed/refractory Wilms tumor, rhabdoid tumor, MPNST, BCOR-driven sarcoma, or another solid tumor that makes a higher than normal amount of XPO1 or has genetic changes that increase the acti…

    Stage

    Phase 2

    Ages

    1 and older

    Site

    Ann & Robert H. Lurie Children'S Hospital of Chicag, Chicago, Illinois

    Locations

    16 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05985161 on ClinicalTrials.gov

14. Indocyanine Green (ICG) Guided Sentinel Lymph Node Mapping for Pediatric Visceral Solid Tumors

    The purpose of the study is to find out the usefulness and safety of a dye called Indocyanine Green (ICG for short). This dye will be used to help the surgeon find lymph nodes draining solid tumors inside the abdomen that need to be removed. This may also help the surgeon to find if the cancer has …

    Stage

    EARLY_Phase 1

    Ages

    Up to 20

    Site

    Lurie Children's Hospital, Chicago, Illinois

    Locations

    3 in total

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT05645523 on ClinicalTrials.gov

15. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northwestern Memorial Hospital, Chicago, Illinois

    Locations

    15 in total

    Run by

    Tango Therapeutics, Inc.

    See if you can join NCT06810544 on ClinicalTrials.gov

16. First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

    The purpose of this study is to determine the safety, blood concentrations and treatment effect of CRB-601 in combination with immunotherapy in patients who have advanced solid tumors (cancer) and have exhausted other therapeutic options.CRB-601 targets a protein called avb8 integrin which is expre…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Chicago, Chicago, Illinois

    Locations

    26 in total

    Run by

    Corbus Pharmaceuticals Inc.

    See if you can join NCT06603844 on ClinicalTrials.gov